FLT3 and acute myeloid leukemia: For instance, patients with FLT3 mutation, in addition to standard chemotherapy treatment, might be considered to receive the tyrosine kinase inhibitors midostaurin in the case of newly diagnosed AML [116], or gilteritinib in the case of FLT-3+ relapsed/refractory AML [117].